Quark Pharmaceuticals Inc., of Fremont, Calif., said the first patient was dosed in a double-masked, randomized sham-controlled phase IIa study to test safety, tolerability and pharmacokinetics of neuroprotective agent QPI-1007 when administered via a single intravitreal injection in patients suffering an acute attack of primary angle closure glaucoma (PACG).